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ABSTRACT
Objective The best approach for Helicobacter pylori 
management remains unclear. An audit process is 
essential to ensure clinical practice is aligned with best 
standards of care.
Design International multicentre prospective non- 
interventional registry starting in 2013 aimed to 
evaluate the decisions and outcomes in H. pylori 
management by European gastroenterologists. Patients 
were registered in an e- CRF by AEG- REDCap. Variables 
included demographics, previous eradication attempts, 
prescribed treatment, adverse events and outcomes. Data 
monitoring was performed to ensure data quality. Time- 
trend and geographical analyses were performed.
Results 30 394 patients from 27 European 
countries were evaluated and 21 533 (78%) first- 
line empirical H. pylori treatments were included for 
analysis. Pretreatment resistance rates were 23% to 
clarithromycin, 32% to metronidazole and 13% to 
both. Triple therapy with amoxicillin and clarithromycin 
was most commonly prescribed (39%), achieving 
81.5% modified intention- to- treat eradication rate. 
Over 90% eradication was obtained only with 10- day 
bismuth quadruple or 14- day concomitant treatments. 
Longer treatment duration, higher acid inhibition and 
compliance were associated with higher eradication 
rates. Time- trend analysis showed a region- dependent 
shift in prescriptions including abandoning triple 
therapies, using higher acid- inhibition and longer 
treatments, which was associated with an overall 
effectiveness increase (84%–90%).
Conclusion Management of H. pylori infection 
by European gastroenterologists is heterogeneous, 
Significance of this study
What is already known on this subject?
 ► Helicobacter pylori affects billions of people 
worldwide and is the main cause of chronic 
gastritis, peptic ulcer disease and gastric cancer.
 ► The ideal regimen to treat the infection remains 
unclear after more than 30 years of experience.
What are the new findings?
 ► Triple therapy prescriptions (reporting cure 
rates of approximately 80%) have decreased, 
especially in those regions with high- 
clarithromycin resistance.
 ► Over 90% eradication was only obtained with 
10- day bismuth quadruple therapies or 14- day 
concomitant treatment.
 ► From 2013 to 2018, the observed shift to longer 
treatment duration, higher acid inhibition 
and compliance provided an increase in the 
effectiveness.
How might it impact on clinical practice in the 
foreseeable future?
 ► The results of this study indicate that the 
management of H. pylori infection by European 
gastroenterologists is heterogeneous, 
frequently suboptimal and discrepant with 
current recommendations. Consensus guideline 
improvements are being slowly incorporated 
into the daily clinical practice, which 
emphasises the importance of regular medical 
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suboptimal and discrepant with current recommendations. Only 
quadruple therapies lasting at least 10 days are able to achieve over 
90% eradication rates. European recommendations are being slowly 
and heterogeneously incorporated into routine clinical practice, which 
was associated with a corresponding increase in effectiveness.
INTRODUCTION
Helicobacter pylori (H. pylori) is a bacterial pathogen with a 
50% worldwide prevalence, being the main cause of chronic 
gastritis, peptic ulcer disease and gastric cancer. However, the 
ideal strategy to manage H. pylori infection remains unclear. The 
diagnostic method, the use of culture and antibiotic susceptibility 
testing, the treatment to prescribe and the test to confirm erad-
ication are debatable, and recommendations have changed over 
time.1–5 Currently, most treatments are prescribed on an empiric 
basis, unaware of the bacterial antibiotic resistance profile. 
Noteworthy, recommendations have changed over time, with 
a shift from triple to quadruple therapies in the last consensus 
conferences.5 6 Therefore, a continuous evaluation of practice 
outcomes using the different management options is required in 
order to achieve high- quality ‘evidence- based medicine’.
It is now accepted that chronic colonisation by H. pylori is 
an infectious disease and should be managed as such.7 For this 
reason, an optimal anti-H. pylori regimen is currently defined 
as one that reliably offers a cure rate of at least 90%, accepted 
as an arbitrary threshold.8 9 Triple therapies, using clarithro-
mycin and amoxicillin, are still the most commonly used first- 
line therapies in spite of their failure in ≥20%–30% of patients. 
Resistance to clarithromycin has been identified as one of the 
major factors affecting H. pylori eradication success, and the 
rate of resistance to this antibiotic is steadily increasing in many 
geographical areas.10 For this reason, non- bismuth quadruple 
regimen, comprising a proton pump inhibitor (PPI), amoxicillin, 
clarithromycin and a nitroimidazole, has more recently been 
used as first- line treatment,5 6 11 12 and has improved the efficacy 
of triple therapy,13 although its efficacy is impaired when dual 
metronidazole- clarithromycin resistance is present.
Bismuth has a strong bacteriostatic effect unaffected by 
resistance and displays a beneficial synergy when combined 
with several antibiotics, allowing to overcome bacterial resis-
tance.14 15 Thus, combinations containing bismuth may be 
promising options in settings where there are high, unknown 
or increasing H. pylori antibiotic resistance rates. Traditionally, 
bismuth has been prescribed in a quadruple regimen containing a 
PPI with tetracycline and metronidazole. However, the treatment 
schemes are complex, and bismuth salts and tetracycline are not 
available in many parts of the world; therefore, these drawbacks 
have caused a tendency to restrict its use to patients with peni-
cillin allergy, or those who require rescue treatments after failure 
of a clarithromycin- containing first- line treatment.16 17 The 
latest approach to H. pylori eradication has been the addition of 
bismuth to the standard triple therapy containing clarithromycin 
and amoxicillin, and this has also achieved encouraging results.18
Considering these treatment combinations, and all of the 
possible optimisations that can be added (length of treatment,19 
dose of PPI,20 among others), it is hard to decide which treat-
ment will provide good results (≥90% cure rates) aligned with 
current recommendations and standards. Evidence from clinical 
trials will always be equivocal because it is impossible to perform 
a single randomised trial to evaluate all existing treatments. 
Network meta- analyses, however, may provide an acceptable 
pooled approach enabling analysis of combinations of data from 
several treatment trials. However, evidence derived from clinical 
trials may not be extrapolated to clinical practice, in which there 
are no restrictive inclusion criteria, and where available care- 
time per patient and patient follow- up are more limited.21
Finally, there is a general delay from publication of recom-
mendations to their implementation in routine clinical prac-
tice,22 23 in which sometimes they reach full penetration after 
being outdated.24 Therefore, scientists recommend long- term 
studies evaluating practice and outcome trends, and tools able 
to provide real- time data from real practice (local, regional and 
global).25
The European Registry on Helicobacter pylori management 
(Hp- EuReg) brings together information on the real clinical prac-
tice of a majority of European countries, including thousands of 
patients with different bacterial resistance patterns and treatment 
accessibility. For these reasons, our aim was to establish a large- 
scale long- term prospective clinical practice study providing an 
overview of the current situation regarding H. pylori manage-
ment. The study would allow not only continuous assessment on 
the integration of clinical recommendations agreed on medical 
consensus but also monitoring of the temporal trends of manage-
ment options and outcomes. These evaluations were aimed to 
decide on the best possible treatment strategies for improvement 
(globally and locally) ensuring that routine clinical practice is 
aligned with best standards of care.
METHODS
European Registry on H. pylori management
The ‘European Registry on H. pylori Management’ (Hp- EuReg) 
is an international multicentre prospective non- interventional 
registry recording information of H. pylori infection manage-
ment since May 2013. Detailed information can be found in the 
published protocol,26 and is summarised in online supplemen-
tary file 2.
Statistical analyses
Continuous variables are presented as mean and SD. Qualitative 
variables are presented as absolute and relative frequencies with 
percentages (%). Graphical representations are used to show 
temporal trends in prescriptions. In the multivariate analysis, the 
effect was evaluated by calculating OR) and 95% CI. Statistical 
significance was considered at p<0.05.
Effectiveness analysis
The main outcome, which is treatment eradication rate, was 
studied in three sets of patients as follows: Intention- to- treat 
(ITT) analysis included all patients registered up to December 
2017, to allow at least a 6- month follow- up, and lost to follow- up 
cases were considered treatment failures. Per- protocol (PP) anal-
ysis included all cases that finished follow- up and had taken at 
least 90% of the treatment drugs, as defined in the protocol. A 
modified ITT (mITT) was designed aiming to reach the closest 
result to those obtained in clinical practice. This mITT included 
for analyses all cases that had completed follow- up (ie, a confir-
matory test—success or failure—was available after eradication 
treatment). Overall (ITT, mITT and PP) analyses were performed 
jointly for patients treated empirically. Additional PP effective-
ness analyses were performed separately in those patients with a 
result of in vitro susceptibility testing.
All 27 countries were clustered in five main regions based both 
on their geographical situation and the 2017 gross domestic 
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More than 100 different treatment schemes were used as 
first- line treatment. They were pooled in 13 categories (online 
supplementary file 4).
Similarly, PPI data were standardised using the PPI acid inhibi-
tion potency as defined by Kirchheiner27 and Graham,28 29 clas-
sified as low, standard and high dose PPI (online supplementary 
file 5).
The relation between eradication rate and age, gender, diag-
nosis, treatment length, PPI dose and compliance was studied 
in the mITT population considering six treatment categories 
(online supplementary file 6).
Mixed logistic regression models were used in a three- step 
strategy: the null model, the global mixed model with interac-
tion between compliance and treatment and the mixed effects 
logistic regression for each treatment (online supplementary file 
7).
RESULTS
From May 2013 to June 2018, 30 394 cases were registered in 
the Hp- EuReg from 27 countries (distribution of patients per 
country is shown in online supplementary table 1). From those, 
21 533 (91%) were first- line therapies included in the current 
analysis (figure 1). Most of them were empirically treated; 
however, in 11% of the cases, bacterial antibiotic resistance data 
were available and were evaluated separately.
Geographical analysis
The 21 533 naïve patients were distributed in the following five 
geographical regions: east (3679), south- east (4299), south- west 
(10 118), centre (1985) and north (1452). The baseline charac-
teristics are shown in table 1. A preliminary inspection showed 
high heterogeneity of practice and outcomes between European 
regions. For instance, 7- day treatment prescription was marginal 
in south- western Europe (1.7%), while it was mostly prescribed 
in south- eastern (60.0%) and northern (53.9%) regions. Most 
common treatments were also region specific: triple therapies 
were favoured in most of Europe (82%–88% in south- eastern 
and northern Europe, 67% in the east and 34% in south- west), 
whereas quadruple therapies were preferred in south- western 
and central Europe (63%–82%). Results of an additional 
cluster comparison performed between regions and the highest 
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recruiting countries are presented in online supplementary table 
2.
Baseline characteristics
Overall baseline characteristics, regional demographics and 
concomitant drug use are presented in table 1.
Diagnosis
Methods used for diagnosis of the infection and confirmation of 
eradication are detailed in online supplementary file 8.
Temporal trend analysis
Figure 2A shows the prescription trends in Europe, where 
prescription shifts were region dependent: triple therapies did 
nearly disappear in south- western and central Europe, while 
they remained in the east, south- east and north. Triple therapies 
decreased from over 50% of prescription in 2013/2015 to less 
than 32% in 2017/2018. Sequential therapies were prescribed in 
8% in 2013 but yearly prescriptions were reduced up to 0.5% in 
2018, and concomitant therapy from 21% in 2013/2014 to 11% 
in 2018. Use of bismuth quadruple therapies increased from 
0%–2% in 2013/2014 to 20% in 2018.
Figure 2B depicts the trends on treatment duration, showing 
an increase in mean duration of treatments from 9.6 days in 
2013, to 9.7 in 2014, 10.0 in 2015, 11.0 in 2016, 11.8 in 2017 
and 11.8 days in 2018, with regional differences. A major change 
that appeared to consistently occur throughout Europe was the 
discontinuation of 7- day therapies, especially in south- eastern 
Table 1 Baseline characteristics of Helicobacter pylori first- line empirical treatments by region
Variable Overall East South- east South- west Centre North
Number of patients 21 533 3679 4299 10 118 1985 1452
Female, N (%) 12 743 (59.2) 2180 (59.0) 2492 (58.0) 6147 (60.8) 1192 (60.0) 732 (50.0)
Age, mean (SD) 50.4 (18.0) 46.4 (15.0) 52.2 (15.0) 50.5 (15.0) 52.2 (15.0) 52.7 (18.0)
Penicillin allergy, N (%) 670 (3.1) 57 (1.5) 126 (2.9) 414 (4.1) 13 (0.7) 60 (4.1)
Indication
  Dyspepsia 17 800 (82.7) 2679 (7.8) 3507 (81.6) 8595 (84.9) 1896 (95.5) 1123 (77.3)
  Ulcer disease 3733 (17.3) 1000 (27.2) 792 (18.4) 1523 (15.1) 89 (4.5) 329 (2.7)
Culture, N (%) 2396 (11.1) 67 (1.8) 219 (5.1) 365 (3.6) 1397 (70.4) 348 (24.0)
  No resistance 1087 (45.4) 20 (29.7) 143 (65.3) 211 (57.8) 552 (39.5) 209 (60.1)
  C 543 (22.7) 22 (32.4) 27 (12.1) 54 (14.9) 401 (28.7) 36 (10.2)
  M 766 (32.0) 25 (37.8) 49 (22.2) 100 (27.5) 444 (31.8) 103 (29.7)
  Dual C+M 321 (13.4) 2 (2.7) 15 (7.1) 18 (5.0) 233 (16.7) 19 (5.6)
Treatment length, N (%)
  7 days 4109 (19.6) 568 (16.2) 2548 (60.0) 165 (1.7) 68 (3.8) 760 (53.9)
  10 days 11 461 (54.8) 2080 (59.2) 981 (23.1) 6220 (62.5) 1691 (94.0) 489 (34.7)
  14 days 5361 (25.6) 867 (24.7) 719 (16.9) 3574 (35.9) 39 (2.2) 162 (11.5)
PPI dose, N (%)
  Low 10 090 (48.9) 1813 (56.6) 2556 (60.6) 3.920 (39.1) 718 (40.3) 1083 (76.9)
  Standard 4211 (20.4) 1135 (35.6) 306 (7.3) 2572 (25.7) 75 (4.2) 123 (8.7)
  High 6325 (30.7) 253 (7.9) 1357 (32.2) 3525 (35.2) 987 (55.4) 203 (14.4)
Compliance, N (%)
  No (<90% drug intake) 592 (3.0) 97 (2.7) 120 (3.0) 287 (3.0) 63 (4.3) 25 (1.8)
  Yes (≥90% drug intake) 18 821 (97.0) 3447 (97.3) 3239 (96.4) 9370 (97.0) 1410 (95.7) 1355 (98.2)
  Unknown 2119 (9.8) 134 (3.6) 940 (24.5) 461 (4.4) 512 (26) 72 (5.0)
Most frequent treatments, N (%)
  PPI- C+A 8478 (39.4) 1775 (48.2) 2571 (59.3) 3160 (31.2) 132 (6.6) 840 (57.9)
  PPI- C+M 1046 (4.9) 28 (0.8) 816 (19.0) 127 (1.3) 4 (0.2) 71 (4.9)
  PPI- A+M 561 (2.6) 56 (1.5) 92 (2.1) 51 (0.5) 3 (0.2) 359 (24.7)
  PPI- A+L 405 (1.9) 227 (6.2) 28 (0.7) 132 (1.3) 6 (0.3) 12 (0.8)
  PPI- C+A+T seq 1228 (5.7) 9 (0.2) 68 (1.6) 4 (0.0) 1128 (56.8) 19 (1.3)
  PPI- C+A+M seq 620 (2.9) 25 (0.7) 175 (4.1) 281 (38.6) 92 (4.6) 47 (3.2)
  PPI- C+A+T conc 190 (0.9) 1 (0.0) 51 (1.2) 0 (0.0) 121 (6.1) 17 (1.2)
  PPI- C+A+M conc 4176 (19.4) 14 (0.4) 250 (5.8) 3910 (38.6) 1 (0.1) 1 (0.1)
  PPI- C+A+B 1756 (8.2) 800 (21.7) 0 (0.0) 956 (9.4) 0 (0.0) 0 (0.0)
  PPI- M+Tc+B 192 (0.9) 30 (0.8) 7 (0.2) 41 (0.4) 99 (5.0) 15 (1.0)
  PPI- M+D+B 59 (0.3) 0 (0.0) 2 (0.0) 56 (0.6) 0 (0.0) 1 (0.1)
  PPI+single capsule* 1351 (6.3) 0 (0.0) 1 (0.0) 1144 (11.3) 189 (9.5) 17 (1.2)
  Other 1471 (6.8) 714 (19.4) 238 (5.5) 256 (2.5) 210 (10.6) 53 (3.7)
Low dose PPI: 4.5–27 mg omeprazole equivalents, two times per day (ie, 20 mg omeprazole equivalents, two times per day), standard dose PPI: 32–40 mg omeprazole 
equivalents, two times per day (ie, 40 mg omeprazole equivalents, two times per day), high dose PPI: 54–128 mg omeprazole equivalents,two times per day (ie, 60 mg 
omeprazole equivalents, two times per day).
*Three- in- one single capsule containing bismuth, tetracycline and metronidazole.
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and northern Europe, where it was still the most common 
therapy duration; however, 7- day therapies were scarcely used 
in other regions (online supplementary table 3).
Figure 3A shows the trends in daily PPI dose (milligrams of 
omeprazole equivalent) by region and year, whereas figure 3B 
shows the temporal trends in mean daily PPI dose. The potency 
of acid inhibition increased from a dose equivalent of 58 mg 
of omeprazole in 2013 to 75 mg in 2018, showing differences 
between regions. Mean daily dose of PPI increased in all regions 
except in central Europe where it decreased in 2017–2018. High 
doses of PPI were mainly used in south- eastern, south- western 
and northern Europe (online supplementary table 3).
Treatment use and overall effectiveness
Overall eradication rate increased from 2013 to 2018 inde-
pendently of the population analysed:
 ► ITT: 70.1% (2013), 72.6% (2014), 74.5% (2015), 76.7% 
(2016), 75.2% (2017), 77.3% (2018).
 ► PP: 84.5% (2013), 85.1% (2014), 85.7% (2015), 87.4% 
(2016), 88.6% (2017), 88.1% (2018).
 ► mITT: 83.9% (2013), 84.5% (2014), 85.2% (2015), 86.8% 
(2016), 88.3% (2017), 87.8% (2018).
The effectiveness trends were region- specific (figure 4): 
Eastern Europe reported eradication rates lower than 70% 
in 2013 and 2014, but achieved 80% mITT in the following 
years. The remaining regions reported an overall treatment 
effectiveness higher than 80% in 2013. These rates increased 
in south- eastern and south- western countries, but remained 
constant in the centre and north.
The effectiveness trends also appeared to be treatment depen-
dent in each region (table 2).
Triple therapy with clarithromycin and amoxicillin was the 
most frequent treatment in all regions but its eradication rate 
remained below 86.6% by mITT. None of the 12 treatments 
considered, except the concomitant therapy with clarithro-
mycin, amoxicillin and tinidazole in the south- east, reached 90% 
effectiveness by mITT, whereas quadruple treatments achieved 
nearly 90% eradication rate. In general, single capsule bismuth 
quadruple treatment was the most successful, achieving approx-
imately 90% mITT eradication in those regions where it was 
prescribed.
The effectiveness was likewise modified depending on the 
duration of treatment. Table 3 shows the impact of treatment 
duration (7, 10 or 14 days). Overall, effectiveness increased with 
longer treatment duration; and this was mostly marked with 
specific treatments, such as the triple therapy with clarithro-
mycin and amoxicillin or when bismuth was added to this triple 
regimen.
An additional univariate subanalysis was performed to eval-
uate the effect of standard (recommended) or high dose PPI 
in those 14- day treatments not reaching 90% effectiveness 
(table 3).
Figure 2 Treatment trends (2013–2018) in Europe per region. (A) Trends in the prescription of treatments. (B) Trends in the duration of treatments. 
A, amoxicillin; B, bismuth salts; C, clarithromycin; Conc, concomitant; D, doxycycline; L, levofloxacin; M, metronidazole; PPI, proton pump inhibitor; 
Seq, sequential; T, tinidazole; Tc, tetracycline.
Figure 3 Trends (2013–2018) in the use of proton pump inhibitors (PPIs) in Europe per region. (A) Trends in the daily dose (low, standard and high) 
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Resistance rates
Data on susceptibility tailored prescription of antibiotics are 
presented in Table 1 and supplementary file 9.
The effect of resistance on eradication rate in the most frequent 
first- line treatments is reported in online supplementary table 4.
Mixed effects logistic regression
Null model
A null model without explanatory variables was developed to 
assess the proportion of variance of the outcome explained by 
grouping the cases in a second level ‘centre’. There were 163 
centres with an average of 89 cases per group. The variance of 
the intercept at centre level was 0.556 (SE 0.110) on the logit 
scale, and intraclass correlation coefficient (ICC) was 0.145; 
meaning the 14.5% of the variance of mITT effectiveness was 
explained by the differences between centres.
Global mixed effects model with interaction between compliance 
and treatment
The global mixed effects model showed a significant effect 
of compliance, with an OR of 6.8 (4.1 to 11.3), as well as an 
effect of treatment on mITT effectiveness. Using quadruple 
therapies with a PPI- clarithromycin- amoxicillin- bismuth as the 
reference category, ORs (95% CI) were as follows: triple with 
clarithromycin- amoxicillin 0.494 (0.39 to 0.622), triple with 
clarithromycin- metronidazole 0.220 (0.156 to 0.311), sequen-
tial with clarithromycin- amoxicillin- metronidazole/tinidazole 
0.452 (0.305 to 0.669), concomitant with clarithromycin- 
amoxicillin- metronidazole/tinidazole 1.130 (0.879 to 1.453), 
and the single capsule bismuth quadruple 1.766 (1.240 to 
2.516), showing significantly higher mITT eradication rates in 
quadruple therapies compared with triple or sequential therapies. 
The interaction between compliance and treatment was signifi-
cant (p=0.02), showing that the difference in eradication rate 
between compliant and non- compliant patients changed from 
treatment to treatment. The interaction between compliance 
and treatments in terms of effectiveness is plotted in figure 5, 
which shows that independently of the treatment considered, 
in compliant patients, the rate of eradication (ranging between 
80% and 95%) was always higher compared with non- compliant 
patients. The effect of non- compliance on the mITT eradication 
rate was lower in concomitant therapy with clarithromycin- 
amoxicillin- metronidazole/tinidazole and quadruple therapy 
with a PPI- clarithromycin- amoxicillin- bismuth than in the 
remaining treatments.
Mixed effects logistic regression by treatment
The final mixed effects logistic regression models were different 
for each treatment considered. To compare treatments easily, a 
tabular summary was built detailing the first level independent 
variables, the random variance component and ICCs for each 
model (table 4), whereas the final models are described in online 
supplementary file 10.
DISCUSSION
In the present manuscript, we analysed the changes in H. pylori 
treatment outcomes throughout a period of 5 years (2013–2018) 
across Europe. We found gastroenterologists’ management of H. 
pylori in Europe is extremely heterogeneous (over 100 different 
first- line schemes), but a set of standard treatment schemes are 
most widely used: two- thirds as triple therapies and a quarter 
as quadruple therapies, and both generally prescribed as 10- day 
regimens. Moreover, our data show that there are strong regional 
differences in practice among European gastroenterologists. In 
this sense, our study shows that the generally unrecommended 
triple therapies have been abandoned in southern Europe, 
and are disappearing in eastern regions; however, their use is 
still widespread in central and northern Europe. This finding 
evidences an incomplete penetration or implementation of the 
last consensus conferences, which recommended switching from 
triple to quadruple therapies.4–6 This lack of update in clinical 
practice causes a high rate of failures (>20% in those patients), 
far from the current arbitrary threshold for acceptance of a 
proposed treatment (≥90% eradication rate).6 8 9
However, our trend analyses of first- line prescriptions 
showed that European gastroenterologists are at last adapting 
their practice to recommendations: some regions have dropped 
or are abandoning triple therapies, causing an overall drop of 
prescriptions from 50% to less than 20%. Furthermore, central, 
northern and south- western Europe are increasing PPI dose and 
lengthening treatment duration (7- day therapies have decreased 
from one- third of prescriptions to less than 1%, being currently 
marginal in all regions). As expected, this improvement in adher-
ence to guidelines and recommendations has correlated with 
an improvement in efficacy rates, reaching in 2018 almost the 
proposed minimum 90% cure rate by ITT.
This manuscript focused on the most relevant first- line treat-
ments used according to either their popularity or their success 
rate. The most commonly prescribed treatment was standard 
triple therapy with a PPI, clarithromycin and amoxicillin, 
achieving lower than 90% eradication rate even when given for 
14 days, as previously described in the literature.30 31 Moreover, 
in our study this treatment was greatly affected by clarithromycin 
resistance, reducing the effectiveness to below 50% in patients 
harbouring resistant strains. In this respect, pretreatment clari-
thromycin resistance in our study was 23%, quite higher than 
the 15% resistance threshold generally considered (although the 
number of patients with susceptibility testing in the Hp- EuReg 
was very limited). However, triple therapy could still be used in 
those areas with low clarithromycin resistance and proven high 
effectiveness.
One of the proposed options chosen to improve triple therapy 
has been to combine PPI, amoxicillin, clarithromycin and 
metronidazole in one single scheme, the so- called ‘non- bismuth 
quadruple treatment’, given as either a sequential or concom-
itant regimen. Non- bismuth quadruple sequential treatment 
comprises PPI with amoxicillin combined during a first phase, 
and a second phase with a PPI, clarithromycin and metronida-
zole, respectively, each phase lasting for at least 5 days. Although 
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Table 2 Effectiveness of most common first- line empirical treatments per region
N
Non- evaluable Failure Success Eradication rate
n % n n ITT PP mITT
East
  PPI- C+A 1775 26 1.5% 739 1010 57.7% 82.3% 81.5%
  PPI- C+M 28 0 0.0% 11 17 60.7% 68.0% 68.0%
  PPI- A+M 56 0 0.0% 22 34 60.7% 75.6% 75.6%
  PPI- A+L 227 0 0.0% 191 36 15.9% 17.1% 16.7%
  PPI- C+A+T seq 9 0 0.0% 9 0 0.0%
  PPI- C+A+M seq 25 0 0.0% 10 15 60.0% 68.2% 68.2%
  PPI- C+A+T conc 1 0 0.0% 1 0 0.0%
  PPI- C+A+M conc 14 0 0.0% 5 9 64.3% 90.0% 90.0%
  PPI- C+A+B 800 3 0.4% 191 606 76.0% 89.6% 89.2%
  PPI- M+Tc+B 30 0 0.0% 6 24 80.0% 92.3% 92.3%
  PPI- M+D+B 0 0
  PPI+single capsule* 0 0
  Other 714 6 0.8% 281 427 60.3% 72.6% 71.9%
  Total in the region 3679 1466 2178 59.8% 77.0% 76.3%
South- east
  PPI- C+A 2571 113 4.4% 1013 1445 58.8% 86.7% 86.6%
  PPI- C+M 816 7 0.9% 217 592 73.2% 85.4% 85.3%
  PPI- A+M 92 0 0.0% 64 28 30.4% 80.0% 80.0%
  PPI- A+L 28 0 0.0% 6 22 78.6% 84.0% 84.6%
  PPI- C+A+T seq 68 0 0.0% 9 59 86.8% 86.8% 86.8%
  PPI- C+A+M seq 175 0 0.0% 37 138 78.9% 84.7% 81.2%
  PPI- C+A+T conc 51 0 0.0% 4 47 92.2% 94.0% 92.2%
  PPI- C+A+M conc 250 0 0.0% 28 222 88.8% 91.7% 91.4%
  PPI- C+A+B 0 0
  PPI- M+Tc+B 7 0 0.0% 1 6 85.7% 100.0% 100.0%
  PPI- M+D+B 2 0 0.0% 1 1 50.0% 50.0% 50.0%
  PPI+single capsule* 1 0 0.0% 0 1 100.0% 100.0% 100.0%
  Other 238 9 3.8% 73 156 68.1% 83.3% 83.0%
  Total in the region 4299 1453 2717 65.2% 86.5% 86.2%
South- west
  PPI- C+A 3160 1 0.0% 682 2477 78.4% 84.3% 83.7%
  PPI- C+M 127 0 0.0% 55 72 56.7% 63.7% 63.2%
  PPI- A+M 51 0 0.0% 13 38 74.5% 79.2% 77.6%
  PPI- A+L 132 1 0.8% 24 107 81.7% 85.2% 84.9%
  PPI- C+A+T seq 4 0 0.0% 1 3 75.0% 100.0% 100.0%
  PPI- C+A+M seq 281 0 0.0% 65 216 76.9% 84.2% 81.8%
  PPI- C+A+T conc 0 0
  PPI- C+A+M conc 3910 12 0.3% 540 3358 86.1% 90.3% 89.8%
  PPI- C+A+B 956 10 1.0% 108 838 88.6% 91.7% 91.6%
  PPI- M+Tc+B 41 0 0.0% 8 33 80.5% 84.6% 82.5%
  PPI- M+D+B 56 0 0.0% 11 45 80.4% 82.4% 81.8%
  PPI+single capsule* 1144 43 3.8% 151 950 86.3% 95.2% 94.6%
  Other 256 5 2.0% 82 169 67.3% 78.3% 76.8%
  Total in the region 10 118 1740 8306 82.7% 88.1% 87.5%
Centre
  PPI- C+A 132 0 0.0% 56 76 57.6% 85.7% 85.4%
  PPI- C+M 4 0 0.0% 1 3 75.0% 100.0% 75.0%
  PPI- A+M 3 0 0.0% 0 3 100.0% 100.0% 100.0%
  PPI- A+L 6 0 0.0% 3 3 50.0% 75.0% 60.0%
  PPI- C+A+T seq 1128 70 6.2% 243 815 77.0% 92.4% 91.7%
  PPI- C+A+M seq 92 0 0.0% 35 57 62.0% 87.5% 86.4%
  PPI- C+A+T conc 121 3 2.5% 14 104 88.1% 96.3% 93.7%
  PPI- C+A+M conc 1 0 0.0% 1 0 0.0%
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it was successfully proposed and implemented in the early 
2000s,32 it has been falling into disuse and it accounted for less 
than 10% of first- line treatments in our study. The eradication 
rate of the sequential therapy in our study (86%) was superior 
to that of triple therapies but still below 90%. Furthermore, 
sequential therapy is affected by single and, especially, by dual 
resistance to clarithromycin and metronidazole,13 scoring below 
80% and 75% in single and dual resistances, respectively.
Non- bismuth quadruple concomitant therapy includes the 
same drugs as sequential therapy but they are all taken together, 
with benefits in terms of simplicity, for both patients and physi-
cians. The literature is clear regarding its superiority to triple 
therapies and, although more debatable, it is better than the 
quadruple sequential therapy as well.12 33–35 Our study showed 
that concomitant regimen during 10 days with standard acid 
inhibition was still unable to reach the 90% cure rate arbi-
trary threshold, but optimised regimens lasting 14 days and/or 
using high dose PPIs did achieve over 90% eradication even in 
clarithromycin- resistant strains.
Another treatment that has resurfaced recently in light of increased 
resistance rates is bismuth quadruple therapy, which contains a PPI, 
bismuth salts, tetracycline and metronidazole.34 36 This combina-
tion has been available as a rather complicated multiprescription 
regimen scheme for many years, but recently, a three- in- one single, 
combination treatment has emerged.37 In the literature, both the 
traditional and the single capsule bismuth quadruple regimens 
achieve eradication rates near or superior to 90% irrespective of 
clarithromycin resistance, and even overcoming metronidazole 
resistance.37–39 In our study, they both achieved this threshold in 
10- day treatments, even though the treated population was biased 
towards a higher prevalence of penicillin allergy, which has been 
proposed to be a risk factor for treatment failure.40 As in previous 
literature,37 metronidazole resistance did not significantly affect 
these bismuth quadruple regimens in our study.
N
Non- evaluable Failure Success Eradication rate
n % n n ITT PP mITT
  PPI- M+Tc+B 99 0 0.0% 28 71 71.7% 95.9% 95.9%
  PPI- M+D+B 0 0
  PPI+single capsule* 189 8 4.2% 82 99 54.7% 98.0% 95.2%
  Other 210 2 1.0% 164 44 21.2% 84.6% 83.0%
  Total in the region 1985 627 1275 67.0% 92.3% 91.2%
North
  PPI- C+A 840 1 0.1% 178 661 78.8% 84.8% 84.3%
  PPI- C+M 71 0 0.0% 21 50 70.4% 76.6% 75.8%
  PPI- A+M 359 0 0.0% 72 287 79.9% 86.5% 86.7%
  PPI- A+L 12 0 0.0% 3 9 75.0% 90.0% 90.0%
  PPI- C+A+T seq 19 0 0.0% 10 9 47.4% 100.0% 100.0%
  PPI- C+A+M seq 47 0 0.0% 13 34 72.3% 71.1% 72.3%
  PPI- C+A+T conc 17 0 0.0% 12 5 29.4% 100.0% 100.0%
  PPI- C+A+M conc 1 0 0.0% 1 0 0.0%
  PPI- C+A+B 0 0
  PPI- M+Tc+B 15 0 0.0% 3 12 80.0% 91.7% 92.3%
  PPI- M+D+B 1 0 0.0% 0 1 100.0% 100.0% 100.0%
  PPI+single capsule* 17 0 0.0% 4 13 76.5% 92.9% 86.7%
  Other 53 0 0.0% 20 33 62.3% 84.2% 84.6%
  Total in the region 1452 337 1114 76.8% 84.7% 84.4%
All regions
  PPI- C+A 8478 141 1.7% 2668 5669 68.0% 84.6% 84.1%
  PPI- C+M 1046 7 0.7% 305 734 70.6% 81.6% 81.3%
  PPI- A+M 561 0 0.0% 171 390 69.5% 84.3% 84.2%
  PPI- A+L 405 1 0.2% 227 177 43.8% 46.6% 46.3%
  PPI- C+A+T seq 1228 70 5.7% 272 886 76.5% 92.1% 91.4%
  PPI- C+A+M seq 620 0 0.0% 160 460 74.2% 83.0% 80.8%
  PPI- C+A+T conc 190 3 1.6% 31 156 83.4% 95.7% 93.4%
  PPI- C+A+M conc 4176 12 0.3% 575 3589 86.2% 90.4% 89.9%
  PPI- C+A+B 1756 13 0.7% 299 1444 82.8% 90.8% 90.6%
  PPI- M+Tc+B 192 0 0.0% 46 146 76.0% 92.4% 91.8%
  PPI- M+D+B 59 0 0.0% 12 47 79.7% 81.5% 81.0%
  PPI+single capsule* 1351 51 3.8% 237 1063 81.8% 95.5% 94.6%
  Other 1471 22 1.5% 620 829 57.2% 76.6% 75.8%
  Total in all regions 21 533 320 1.5% 5623 15 590 73.5% 86.2% 85.6%
*Three- in- one single capsule containing bismuth, tetracycline and metronidazole.
A, amoxicillin; B, bismuth salts; C, clarithromycin; Conc, concomitant; D, doxycycline; L, levofloxacin; M, metronidazole; mITT, modified intention- to- treat; PP, per protocol; PPI, 
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Finally, bismuth may also be combined with clarithromycin 
and amoxicillin to improve the efficacy of standard triple 
therapy. This approach has not been widely used in the litera-
ture, but a few studies have been published recently with encour-
aging results and have promoted a change in practice.41 42 Our 
results with this treatment were also promising when prescribed 
for 14 days, scoring over 90% eradication by mITT.
In our mixed multilevel analysis, several factors were found to 
be independently associated with treatment effectiveness, espe-
cially adherence to treatment, with a global OR of approximately 
7. Remarkably, compliance was excellent (97%) and was indeed 
the factor which was mostly associated with higher eradication 
rate in all treatment categories evaluated, with an OR ranging 
from 4 (concomitant treatment) to 50 (quadruple therapy with 
clarithromycin, amoxicillin and bismuth). Additionally, use of 
the recommended dose of PPI improved cure rates in all treat-
ment categories, although when high instead of standard doses 
were used, no additional benefit was found as shown in table 4.
Findings from the present study should be interpreted with 
caution on account of a number of limitations. First of all, 
this study is not a randomised controlled clinical trial; there-
fore, comparisons of treatments must be taken with care, due 
to unidentified allocation biases that may affect effective-
ness. These include different local resistance rates, the age of 
treatment groups, treatment and care costs for patients and 
providers, and the use of the mITT analysis versus the tradi-
tional ITT (which could overestimate eradication) among others. 
However, these limitations are inherent to studies focused on 
clinical practice, which are necessary to elucidate the outcomes 
in routine practice.
Another drawback is that inclusion rates and numbers varied 
between centres, regions and countries according to the number 
of H. pylori infections managed in each outpatient clinic. For 
example, standard clinics in regions with low infection preva-
lence may obviously attend a lower number of H. pylori- infected 
patients, thus affecting their inclusion rates. Although results 
may not be fully representative of the general population, it is 
important to mention that in those highest recruiting countries 
such as Spain, there was a wide variety of centre types (large 
hospitals vs small outpatients clinics) and therefore this could 
balance the distribution and the representativeness of the popu-
lation. In any case, in our sensitivity analysis, we did not iden-
tify any significant bias derived from high versus low inclusion 
countries. In addition, even if we may think heterogeneity was 
inevitably present, it is important to highlight that the standard 
triple therapy did not reach an optimal effectiveness in any of 
the regions; and, by contrast, in all the regions, all quadruple 
regimens (concomitant, single capsule bismuth quadruple 
Table 3 Effectiveness of first- line empirical treatments according to duration
ITT eradication rate PP eradication rate mITT eradication rate
Treatment duration Treatment duration Treatment duration
N 7 days 10 days 14 days N 7 days 10 days 14 days N 7 days 10 days 14 days
PPI- C+A* 8337 60.4% 71.5% 73.2% 6647 83.0% 84.8% 86.7% 6743 82.7% 84.2% 86.2%
PPI- C+M* 1039 74.0% 57.4% 54.3% 898 84.8% 67.3% 67.9% 903 84.4% 66.7% 67.9%
PPI- A+M 561 69.3% 77.4% 25.0% 458 80.7% 85.9% 80.0% 463 80.8% 85.7% 80.0%
PPI- A+L 404 8.6% 78.0% 74.2% 371 8.9% 86.8% 85.2% 382 8.8% 85.4% 85.2%
PPI- C+A+T seq 1158 NA 77.5% NA 957 NA 92.1% NA 969 NA 91.5% NA
PPI- C+A+M seq* 620 NA 74.4% NA 528 NA 82.9% NA 569 NA 80.8% NA
PPI- C+A+T conc 187 NA 85.4% 89.5% 162 NA 95.5% 100.0% 167 NA 92.8% 100.0%
PPI- C+A+M conc 4164 NA 84.8% 88.2% 3891 95.0% 88.9% 92.2% 3992 90.9% 88.3% 92.1%
PPI- C+A+B 1743 50.0% 74.6% 86.6% 1577 76.9% 86.6% 92.6% 1594 76.9% 86.2% 92.4%
PPI- M+Tc+B 192 NA 75.3% 83.3% 157 NA 93.8% 88.2% 159 NA 93.1% 88.2%
PPI- M+D+B 59 NA 93.8% 78.0% 54 NA 93.3% 81.1% 58 NA 93.8% 80.0%
PPI+single capsule† 1300 NA 82.1% NA 1102 NA 95.4% NA 1124 NA 94.5% NA
Other 1449 62.1% 73.4% 54.5% 1073 73.7% 85.0% 60.4% 1094 73.7% 84.4% 59.7%
Total 21 213 61.1% 76.9% 79.6% 17 875 78.5% 87.8% 88.3% 18 217 78.2% 87.0% 88.0%
*An effectiveness univariate analysis was performed accounting 10- day or 14- day treatments prescribed together with high doses PPI only, and following therapies reached over 
90% mITT eradication rate: 14- day PPI- C+A (89.6%), 10- day PPI- C+A+M seq (91.6%), 10- day or14- day PPI- C+A+M conc (both 92.7% and 92.8%), 10- day PPI- C+A+B (95.5%), 
10- day PPI- M+Tc+B (95.2%). A χ2 test was also performed and significant comparisons (10 days vs 14 days with high- dose PPIs) were reported in the table (*). Additional 
pair- wise comparison (by means of Chi2 test and Fisher exact test) were performed between following treatments: 10- day sequential, 14- day concomitant and 10- day bismuth 
quadruple: statistically significant differences (p<0.001) were found in all comparisons in favour of the 14- day concomitant and 10- day bismuth quadruple therapies.
†Three- in- one single capsule containing bismuth, tetracycline and metronidazole.
A, amoxicillin; B, bismuth salts; C, clarithromycin; Conc, concomitant; ITT, intention- to- treat; L, levofloxacin; M, metronidazole; mITT, modified- intention- to treat; NA, Not 
applicable; PP, per protocol; PPI, proton pump inhibitor; Seq, sequential; Tc, tetracycline.
Figure 5 Eradication rate (and 95% CI) by treatment according to 
compliance. A, amoxicillin; B, bismuth salts; C, clarithromycin; Conc, 
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and bismuth- amoxicillin- clarithromycin quadruple therapies) 
achieved ≈90% eradication rates, which confers consistency to 
the cluster- by- cluster analysis of the data.
Finally, our intention to study clinical practice forced us to 
register as many open management options as possible; this 
increases heterogeneity and sometimes limits the amount of data 
obtainable from each case. For example, individual antibacterial 
resistance was available in a relatively low proportion of cases, 
translating what happens in day- to- day clinical practice in Europe. 
In the future, PCR testing could ease bacterial antibiotic suscepti-
bility evaluation if such method is shown to be reliable in faecal 
samples, which would avoid invasive testing such as endoscopy.
In contrast to these limitations, we believe that this type of study 
has a number of strengths that compensate the weaker areas. The 
open inclusion criteria ensure that our data represent the real clin-
ical practice of the participant centres, and it allow the evaluation 
of the widest range of therapeutic options and patient contexts. 
Although data are heterogeneous, the analyses showed that the 
measure of the effect is consistent throughout Europe. Moreover, 
the large number of recruiters and countries has provided, to our 
knowledge, the largest international prospective series on H. pylori 
treatment under a common research protocol. This has enabled us 
to perform multivariate analyses to control for confounding vari-
ables, data bias and heterogeneity, to develop regional and time- 
trend approaches. The inclusion of centres with different levels of 
experience in H. pylori gave us a wide view of real practice. Finally, 
a high- quality method has been used to register, store, manage and 
monitor the data by the use of Online Platform for Collaborative 
Research AEG- REDCap, which provides stability and coherence to 
the data with programmed and real- time quality controls, queries, 
reports and statistics.
In light of these results, we may conclude that in order to obtain 
over 90% eradication rates consistently, to avoid retreatment and 
to prevent patient dropout, physicians should be encouraged to 
use quadruple therapies, because these are the only regimens that 
consistently achieve eradication rates ≥90%. Those treatments 
were as follows: 14- day non- bismuth quadruple concomitant 
therapy (PPI, amoxicillin, clarithromycin and metronidazole), 
14- day standard triple plus bismuth (PPI, bismuth, amoxicillin 
and clarithromycin) and 10- day bismuth quadruple therapy (PPI, 
bismuth, tetracycline and metronidazole). If antibiotic resistance 
rates are high in the local geographical area, and especially if dual 
resistance to clarithromycin and metronidazole is greater than 
15%, bismuth quadruple therapy may be the most reliable choice.
Prescribing physicians must also take into consideration that 
regardless of the treatment chosen or the clinical context, compli-
ance with treatment was the most relevant factor for achieving 
successful eradication, so treatment, procedures and expectations 
must be carefully explained to the patient.
Although overall H. pylori cure rates in the European Registry 
are relatively disappointing, different regions of Europe are slowly 
and heterogeneously incorporating recommended practices such 
as prescribing quadruple therapies for 2 weeks with an increased 
dose of acid inhibition. The observed ongoing adaptation of real 
clinical practice to recommendations gives room for hope, espe-
cially considering the parallel improvement (up to 10% in some 
regions) in overall efficacy in Europe in only 5 years.
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manuscript draft and approved the submitted manuscript); Marina Fedorovna 
Osipenko (Novosibirsk State Medical University Novosibirsk Russia Acquired data, 
critically reviewed the manuscript draft and approved the submitted manuscript); 
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Sergii Hryhorovych (Melashchenko Vinnitsa National Medical University Vinnytsia 
Ukrania Acquired data, critically reviewed the manuscript draft and approved the 
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the submitted manuscript); Mette Wildner- Christensen (Odense University Hospital 
(OUH) Svendborg Denmark Acquired data, critically reviewed the manuscript draft 
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submitted manuscript); Yana Valerieva (University Hospital Tsaritsa Yoanna- ISUL Sofia 
Bulgaria Acquired data, critically reviewed the manuscript draft and approved the 
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manuscript draft and approved the submitted manuscript); Alla Kononova 
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manuscript draft and approved the submitted manuscript); Sergey Kolbasnikov (The 
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reviewed the manuscript draft and approved the submitted manuscript); Michael 
Selgrad (Otto- von Guericke University Magdeburg Germany Acquired data, critically 
reviewed the manuscript draft and approved the submitted manuscript); Jolanta 
Sumskiene (Lithuanian University of Health Sciences Hospital Lithuania Lithuania 
Acquired data, critically reviewed the manuscript draft and approved the submitted 
manuscript); Jonathan Hirsch (Meir Medical Center Kfar Saba Israel Acquired data, 
critically reviewed the manuscript draft and approved the submitted manuscript); 
Francisco Javier Zozaya Larequi (Hospital Universitario Donostia San Sebastián Spain 
Acquired data, critically reviewed the manuscript draft and approved the submitted 
manuscript); Alain C Burette (Chirec clinique de la Basilique and clinique Edith Cavell 
Brussels Belgium Acquired data, critically reviewed the manuscript draft and 
approved the submitted manuscript); Nora Dancs Petz- Aladar (Teaching Hospital 
Gyor Hungary Acquired data, critically reviewed the manuscript draft and approved 
the submitted manuscript); Janne Rajala Herttoniemi (Hospital Helsinky Finland 
Acquired data, critically reviewed the manuscript draft and approved the submitted 
manuscript); Christina Reimer (Hvidovre Hospital Hvidovre Denmark Acquired data, 
critically reviewed the manuscript draft and approved the submitted manuscript); 
Diogo Libanio (Gastroenterology Department Instituto Portugues de Oncologia do 
Porto (IPO- Porto) Porto Portugal Acquired data, critically reviewed the manuscript 
draft and approved the submitted manuscript); Pedro Pimentel- Nunes 
(Gastroenterology Department Instituto Portugues de Oncologia do Porto (IPO- Porto) 
Porto Portugal Acquired the data, critically reviewed the manuscript draft and 
approved the submitted manuscript); Ivailo Evstatiev (University Hospital St Ekaterina 
Sofia Bulgaria Acquired data, critically reviewed the manuscript draft and approved 
the submitted manuscript); Juozas Kupcinskas (Lithuanian University of Health 
Sciences Kaunas Lithuania Acquired data, critically reviewed the manuscript draft 
and approved the submitted manuscript); Mikhail Butov (State Budgetary 
Educational Institution of Higher Professional Education Ryazan State I.P. Pavlov 
Medical University of the Ministry of Public Health of Russian Federation (SB?IHPE 
RSMU of Ministry of Public Health of Russian Federation) Department of 
Propaedeutics of Internal Diseases Ryazan Russia Acquired data, critically reviewed 
the manuscript draft and approved the submitted manuscript); Peter Mensink 
(Medisch Spectrum Twente Enschede The Netherlands Acquired data, critically 
reviewed the manuscript draft and approved the submitted manuscript); T Tang 
(IJsselland Ziekenhuis Capelle aan de Ijssel The Netherlands Acquired data, critically 
reviewed the manuscript draft and approved the submitted manuscript); Andrey 
Yurevich Baranovsky (North- Western State Medical University named after 
I.I.Mechnicov Saint- Petersburg Russia Acquired data, critically reviewed the 
manuscript draft and approved the submitted manuscript); Natalya Marchenko 
(North- Western State Medical University named after I.I. Mechnikov Saint- Patarsburg 
Russia Acquired data, critically reviewed the manuscript draft and approved the 
submitted manuscript); Boris Bastens (CHC Liege Liege Belgium Acquired data, 
critically reviewed the manuscript draft and approved the submitted manuscript); 
Lyudmila Mateva ("University Hospital St. Ivan Rilski Sofia Bulgaria Acquired data, 
critically reviewed the manuscript draft and approved the submitted manuscript); 
Dominique Lamarque (Hôpital Ambroise- Paré Boulogne- Billancourt (Paris) France 
Acquired data, critically reviewed the manuscript draft and approved the submitted 
manuscript); Leonardo Henry (Eusebi Department of Medical and Surgical Sciences 
(DIMEC), University of Bologna, Gastroenterology and Endoscopy Unit, Policlinico S.
Orsola- Malpighi Bologna Italy Acquired the data, critically reviewed the manuscript 
draft and approved the submitted manuscript); Mario Ribeiro (FMUP/IPATIMUP Porto 
Portugal Acquired data, critically reviewed the manuscript draft and approved the 
submitted manuscript); M ter Borg (Maxima Medisch Centrum Eindhoven The 
Netherlands Acquired data, critically reviewed the manuscript draft and approved the 
submitted manuscript); Alexander C Ford (Leeds Teaching Hospitals Trust Leeds UK 
Acquired data, critically reviewed the manuscript draft and approved the submitted 
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Acquired data, critically reviewed the manuscript draft and approved the submitted 
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